These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 9769784

  • 21. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC.
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [Abstract] [Full Text] [Related]

  • 22. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

  • 23. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
    [Abstract] [Full Text] [Related]

  • 24. Chemotherapy of urothelial tract tumors.
    Yagoda A.
    Cancer; 1987 Aug 01; 60(3 Suppl):574-85. PubMed ID: 3297286
    [Abstract] [Full Text] [Related]

  • 25. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 01; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 26. [Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer].
    Gohji K, Takenaka A, Goto A, Hara I, Matsumoto O, Kamidono S, Hamami G, Itani A, Harada K, Tadera N.
    Nihon Hinyokika Gakkai Zasshi; 1989 Mar 01; 80(3):321-8. PubMed ID: 2659869
    [Abstract] [Full Text] [Related]

  • 27. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
    Miura N, Numata K, Azuma K, Hashine K, Sumiyoshi Y.
    Nihon Hinyokika Gakkai Zasshi; 2007 May 01; 98(4):589-94. PubMed ID: 17564101
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer.
    Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Higgins G, Boyle MG, Herr H, Bajorin DF.
    Cancer Invest; 2000 May 01; 18(7):626-34. PubMed ID: 11036470
    [Abstract] [Full Text] [Related]

  • 29. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Scher HI.
    J Urol; 1992 Nov 01; 148(5):1625-6. PubMed ID: 1433578
    [No Abstract] [Full Text] [Related]

  • 30. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 31. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ, Iscoe N, Tannock IF.
    J Urol; 1993 Oct 15; 150(4):1131-4. PubMed ID: 8371371
    [Abstract] [Full Text] [Related]

  • 32. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M, Meguro N, Maeda O, Saiki S, Kinouchi T, Usami M, Kotake T.
    Cancer Chemother Pharmacol; 1994 Oct 15; 35 Suppl():S9-13. PubMed ID: 7527736
    [Abstract] [Full Text] [Related]

  • 33. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    J Urol; 1995 Jan 15; 153(1):47-52. PubMed ID: 7966789
    [Abstract] [Full Text] [Related]

  • 34. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    J Clin Oncol; 2001 May 15; 19(10):2638-46. PubMed ID: 11352955
    [Abstract] [Full Text] [Related]

  • 35. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N.
    Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654
    [Abstract] [Full Text] [Related]

  • 36. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
    Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C.
    Cancer Chemother Pharmacol; 1992 Dec 15; 30 Suppl():S72-6. PubMed ID: 1394823
    [Abstract] [Full Text] [Related]

  • 37. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 15; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 38. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg LR.
    J Urol; 1988 Mar 15; 139(3):461-9. PubMed ID: 3343727
    [Abstract] [Full Text] [Related]

  • 39. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
    Obata K, Kobayashi H, Takaba H, Yokoi K, Hikosaka A.
    Hinyokika Kiyo; 1994 Oct 15; 40(10):939-44. PubMed ID: 7527613
    [Abstract] [Full Text] [Related]

  • 40. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M, Matsumoto K, Tabata K, Minamida S, Fujita T, Satoh T, Iwamura M, Baba S.
    Jpn J Clin Oncol; 2011 Oct 15; 41(10):1214-20. PubMed ID: 21903707
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.